Asia-Pacific Cell and Gene Therapy Manufacturing QC Market to Grow with a CAGR of 6.90% through 2030
The growing
advancement in healthcare infrastructure is expected to drive the Asia-Pacific
Cell and Gene Therapy Manufacturing QC Market growth in the forecast period,
2026-2030.
According to
TechSci Research report, “Asia-Pacific Cell and Gene Therapy Manufacturing
QC Market – By Country, Competition, Forecast &
Opportunities, 2030F”, the Asia-Pacific Cell and Gene Therapy Manufacturing
QC Market stood at USD 526.30 million in 2024 and is anticipated to grow with a
CAGR of 6.90% in the forecast period, 2026-2030.
The Asia-Pacific Cell and Gene Therapy Manufacturing QC market is experiencing
rapid growth as the region becomes a global leader in the development and
commercialization of innovative therapies.
The increasing
demand for personalized medicine, particularly for the treatment of complex
diseases such as cancer and genetic disorders, has driven the need for highly
efficient and reliable manufacturing processes. Cell and gene therapies, such
as CAR-T (Chimeric Antigen Receptor T-cell) therapies and gene editing
techniques, require rigorous quality control (QC) procedures to ensure the
safety, potency, and genetic integrity of the biologics involved. The market
for QC services is expanding as these therapies advance from clinical trials to
commercial production. Companies are adopting state-of-the-art technologies
like next-generation sequencing (NGS), real-time data monitoring, and
automation to streamline QC processes, reduce the risk of contamination, and
meet strict regulatory requirements. The growing biotechnology infrastructure,
particularly in countries like China, Japan, and South Korea, is further
contributing to the market's expansion.
In addition to
the technological advancements, regulatory frameworks across the Asia-Pacific
region are evolving to accommodate the unique needs of cell and gene therapies.
National and regional regulatory bodies are tightening quality standards for
the manufacturing of these therapies, driving the demand for comprehensive QC
services that can ensure compliance. This includes everything from testing for
viral vector contamination to ensuring genetic stability and ensuring that
cell-based therapies meet the potency requirements. The rise of contract
manufacturing organizations (CMOs) and contract development and manufacturing
organizations (CDMOs) in the region is also helping to accelerate the QC market
by offering specialized services and expertise to biotech companies. As the
cell and gene therapy landscape continues to evolve, the Asia-Pacific region
will play a pivotal role in shaping the future of the Asia-Pacific Cell and Gene Therapy Manufacturing QC, driving the need for more precise, scalable, and cost-effective quality
control solutions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Asia-Pacific Cell and Gene Therapy Manufacturing QC Market”
The Asia-Pacific
Cell and Gene Therapy Manufacturing QC Market is segmented into offering,
application, technology, regional distribution, and company.
Based on application,
the safety testing category is showing the fastest growth in the Asia-Pacific
Cell and Gene Therapy Manufacturing QC market, driven by the increasing demand
for thorough and reliable assessments of therapeutic products. As cell and gene
therapies progress through clinical trials and toward commercialization,
ensuring patient safety becomes paramount. These therapies involve living
organisms, such as genetically modified cells or viral vectors, which can
introduce risks like immune reactions, contamination, or unintended genetic
alterations. Safety testing helps to identify and mitigate these risks by
verifying the purity, sterility, and genetic stability of the therapies,
ensuring they meet regulatory safety standards.
Based on country, Japan is
experiencing significant growth in the Asia-Pacific Cell and Gene Therapy
Manufacturing QC market, driven by its strong healthcare infrastructure,
advanced biotechnology sector, and favorable regulatory environment. As one of
the leading countries in the development and commercialization of cell and gene
therapies, Japan is at the forefront of integrating cutting-edge technologies
into its manufacturing processes. The demand for high-quality, efficient
quality control (QC) services is rapidly increasing as more cell and gene
therapies, such as CAR-T cell therapies and gene editing techniques, progress
through clinical trials and toward market approval. Japan’s regulatory
agencies, such as the Pharmaceuticals and Medical Devices Agency (PMDA), have
set high standards for the quality and safety of these therapies, making
stringent QC protocols essential to ensure compliance with global regulations.
Major companies
operating in Asia-Pacific Cell and Gene Therapy Manufacturing QC Market are:
- Bio-Techne
Corporation
- Danaher
Corporation
- F.
Hoffmann-La Roche Ltd
- Lonza
- Miltenyi
Biotec B.V. & Co. KG
- Sartorius
AG
- Thermo
Fisher Scientific Inc.
- WuXi
AppTec
- Fujifilm
Holdings Corporation
- Merck
KGaA
Download Free Sample Report
Customers can
also request for 10% free customization on this report
"The increasing
demand for advanced, high-quality manufacturing processes is significantly
driving the growth of the Cell and Gene Therapy Manufacturing QC market in the
Asia-Pacific region. As cell and gene therapies continue to advance in both
research and clinical applications, the need for precise, reliable quality
control measures is becoming increasingly vital. The integration of
cutting-edge technologies such as automation, artificial intelligence
(AI)-driven analytics, and real-time monitoring systems is essential to ensure
the safety, potency, and genetic stability of these therapies. As the market
evolves, ongoing innovations in bioprocessing, testing methodologies, and
regulatory frameworks will play a crucial role in ensuring the consistent
production of high-quality therapies. These advancements will ultimately
transform the landscape of cell and gene therapy manufacturing in the
Asia-Pacific region, making it more efficient, reliable, and capable of meeting
the diverse needs of healthcare providers and patients," said Mr. Karan
Chechi, Research Director at TechSci Research, a research-focused management
consulting firm.
“Asia-Pacific
Cell and Gene Therapy Manufacturing QC Market By Offering (Products, Services),
By Application (Safety Testing, Potency Testing, Identity Testing, Stability
and Genetic Fidelity Testing, Others), By Technology (Polymerase Chain
Reaction, Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked
Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western
Blotting, Next-Generation Sequencing, Electrophoresis, Others), By Country, Competition Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of Asia-Pacific Cell and Gene Therapy
Manufacturing QC Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Asia-Pacific
Cell and Gene Therapy Manufacturing QC Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com